Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #204: FDA Keeps GH Research’s 5-MeO-DMT on Ice; Makary’s Priority Voucher Pilot Launches, Mentions Innovative PTSD Treatments; HALT Fentanyl Act Could Streamline Schedule I Research

July 25, 2025

Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression • Spravato’s Monotherapy Success Puts Pressure on Psychedelics Developers • Longevity Crowd Hypes Psilocybin Study But Researchers Urge Caution • Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch? • 3 Years of Psychedelics Access via Canada’s Special Access Programme • The New Neuroplastogen Developer on the Block • and more…

Pα+ Psychedelic Bulletin #203: Norway Considers Funding Off-Label Ketamine for TRD; Longevity Crowd Hypes Psilocybin Study; Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch?

July 14, 2025

Norway’s Health System Considers Funding Off-Label Ketamine for Treatment-Resistant Depression • Spravato’s Monotherapy Success Puts Pressure on Psychedelics Developers • Longevity Crowd Hypes Psilocybin Study But Researchers Urge Caution • Will State-Legal Psychedelics Eat Psychedelic Pharma’s Lunch? • 3 Years of Psychedelics Access via Canada’s Special Access Programme • The New Neuroplastogen Developer on the Block • and more…

Psychedelic Funding Update: Q2 2025

July 9, 2025

Q1 2025 saw around $152M flow into psychedelics companies, with Lykos Therapeutics’ $50M Series B round representing one of the first major private financings in quite some time. Explore key trends, public vs. private dynamics, and how the markets are reacting to trial and regulatory news in our Q1 roundup.

From Senate to Psychedelics: Kyrsten Sinema’s Ibogaine Advocacy Playbook

July 7, 2025

In a candid conversation with Psychedelic Alpha’s Josh Hardman, former U.S. Senator Kyrsten Sinema shares her case for ibogaine, sidesteps what she describes as ‘drama’, and lays out a strategy for funding research into the atypical psychedelic. Framing FDA approval as the north star, Sinema positions ibogaine as a transformative treatment option for conditions ranging from PTSD through to traumatic brain injury and Parkinson’s.

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more